Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYAI NASDAQ:ENLV NASDAQ:GBIO NASDAQ:JBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYAIDyadic International$0.98+0.5%$0.99$0.91▼$2.20$29.34M0.8854,401 shs29,447 shsENLVEnlivex Therapeutics$1.20-2.4%$1.07$0.81▼$1.76$29.09M0.79132,618 shs57,646 shsGBIOGeneration Bio$0.52-7.7%$0.38$0.30▼$3.65$37.88M2.59464,138 shs1.91 million shsJBIOJade Biosciences$9.51+7.9%$0.00$6.57▼$105.00$7.41M1.06540,307 shs171,880 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYAIDyadic International+0.51%-1.99%+6.52%-20.33%-31.47%ENLVEnlivex Therapeutics-2.44%-10.45%+16.50%+38.73%-13.67%GBIOGeneration Bio-7.72%+39.82%+36.49%+33.69%-82.85%JBIOJade Biosciences+7.95%-9.60%+14.72%+950,999,900.00%+950,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYAIDyadic International3.0283 of 5 stars3.55.00.00.02.71.70.0ENLVEnlivex Therapeutics2.6917 of 5 stars3.73.00.00.02.70.80.6GBIOGeneration Bio3.7605 of 5 stars3.55.00.00.01.63.31.3JBIOJade Biosciences2.027 of 5 stars3.50.00.00.01.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYAIDyadic International 3.00Buy$6.00512.24% UpsideENLVEnlivex Therapeutics 3.33Buy$10.00733.33% UpsideGBIOGeneration Bio 3.00Buy$7.331,306.47% UpsideJBIOJade Biosciences 3.00Buy$15.0057.73% UpsideCurrent Analyst Ratings BreakdownLatest JBIO, ENLV, GBIO, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.005/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYAIDyadic International$3.34M8.82N/AN/A$0.08 per share12.25ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AGBIOGeneration Bio$19.89M1.76N/AN/A$1.29 per share0.40JBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYAIDyadic International-$5.81M-$0.20N/AN/AN/A-163.94%-233.69%-59.37%8/12/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)GBIOGeneration Bio-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)JBIOJade Biosciences-$69.63M-$59.65N/A∞N/AN/A-60.01%-54.32%N/ALatest JBIO, ENLV, GBIO, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025DYAIDyadic International-$0.06N/AN/AN/A$0.60 millionN/A8/6/2025Q2 2025GBIOGeneration Bio-$0.28N/AN/AN/A$2.51 millionN/A5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/14/2025Q1 2025DYAIDyadic InternationalN/A-$0.07N/A-$0.07N/A$0.39 million5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYAIDyadic InternationalN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYAIDyadic International5.403.983.98ENLVEnlivex TherapeuticsN/A7.207.20GBIOGeneration BioN/A8.438.43JBIOJade BiosciencesN/A32.0132.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYAIDyadic International27.95%ENLVEnlivex Therapeutics1.02%GBIOGeneration Bio95.22%JBIOJade BiosciencesN/AInsider OwnershipCompanyInsider OwnershipDYAIDyadic International29.50%ENLVEnlivex Therapeutics12.28%GBIOGeneration Bio21.80%JBIOJade Biosciences24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYAIDyadic International730.09 million21.21 millionOptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableGBIOGeneration Bio15067.04 million52.42 millionOptionableJBIOJade Biosciences20840,000632,000N/AJBIO, ENLV, GBIO, and DYAI HeadlinesRecent News About These CompaniesJade Biosciences (NASDAQ:JBIO) Coverage Initiated at Jefferies Financial GroupJuly 16 at 4:09 AM | americanbankingnews.comJBIO - Jade Biosciences Inc Financials | MorningstarJuly 11, 2025 | morningstar.comMJade Biosciences, Inc. to Participate in H.C. Wainwright and Stifel Biotech Investor ConferencesJuly 8, 2025 | quiverquant.comQJade Biosciences to Participate in Two Upcoming Investor ConferencesJuly 8, 2025 | globenewswire.comJade Biosciences Inc. Stock Grades | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences Inc. Research & Ratings | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences appoints Brad Dahms as new CFOJuly 2, 2025 | investing.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and Innovation - NasdaqJuly 2, 2025 | nasdaq.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and InnovationJuly 1, 2025 | quiverquant.comQJade Biosciences Appoints Brad Dahms as Chief Financial OfficerJuly 1, 2025 | globenewswire.com2 Small-Cap Stocks Under $10 to Buy With Big PotentialJune 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJBIO, ENLV, GBIO, and DYAI Company DescriptionsDyadic International NASDAQ:DYAI$0.98 +0.01 (+0.51%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$0.99 +0.01 (+1.43%) As of 07/17/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Enlivex Therapeutics NASDAQ:ENLV$1.20 -0.03 (-2.44%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$1.30 +0.10 (+7.92%) As of 07/17/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Generation Bio NASDAQ:GBIO$0.52 -0.04 (-7.72%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$0.51 -0.01 (-2.76%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Jade Biosciences NASDAQ:JBIO$9.51 +0.70 (+7.95%) As of 07/17/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
